Why the study?
Does thromboelastometry (ROTEM) accurately detect residual heparin to guide additional protamine administration in patients after coronary artery surgery with CPB?
Does thromboelastometry (ROTEM) accurately detect residual heparin to guide additional protamine administration in patients after coronary artery surgery with CPB?
Answers are grounded in this paper and cite their sources.
ROTEM may be a useful bedside monitor to prevent unnecessary administration of excess protamine, which can contribute to coagulopathy after cardiac surgery.
Despite growing concerns about heparin for anticoagulation, including heparin-induced thrombocytopenia and potential antigenicity, heparin is used for perioperative anticoagulation because it is rapidly reversible with protamine. Although novel anticoagulants, including direct thrombin inhibitors and newer anti-Xa inhibitors, including fondaparinux, rivaroxaban, and apibixiban are emerging into clinical practice, none of these drugs are acutely reversible. Thus, heparin remains the drug of choice for cardiac and vascular surgical procedures. In early 2008, reports of acute hypersensitivity reactions consistent with anaphylaxis seriously threatened our heparin supply. A contaminant was identified as an unusual oversulfated form of chondroitin sulfate.1 The reason heparin is reversible is because, similar to chondroitin sulfate, they both are glycosaminoglycans that contain highly charged molecular species that facilitate binding to basic molecules like protamine. The oversulfated chondroitin sulfate molecule that was a contaminant was demonstrated to activate inflammatory cascades, including the kinin– kallikrein pathway, and the complement cascade to generate C3a and C5a, potent anaphylatoxins to produce an anaphylactic clinical syndrome.1 Despite recent reports of reactions to heparin, protamine is equally problematic for producing serious adverse reactions. Protamine is isolated from salmon sperm and contains approximately 70% arginine, a basic compound, that allows it to bind to heparin and reverse the acidic heparin by forming a simple acid-base interaction.2 Adverse reactions to protamine include anaphylaxis, acute pulmonary vasoconstriction, right ventricular failure, and hypotension via direct and indirect mechanisms.2 Despite all the reported problems with protamine, it is the only drug currently available to reverse heparin anticoagulation. How many times have we been asked to administer additional protamine despite a normal activated clotting time (ACT) because the patient was bleeding? Routinely, anesthesiologists administer additional protamine, but is there potentially any disadvantage or benefit in doing this? In this issue of Anesthesia & Analgesia, Mittermayr et al.3 investigated whether protamine’s effects on hemostasis could be detected using thromboelastometry (ROTEM®, Pentapharm GmbH, Munich, Germany) and other laboratory tests to evaluate residual heparin levels. After coronary artery surgery with cardiopulmonary bypass (CPB), 22 patients received an initial dose of protamine based on the total amount of heparin administered. Additional protamine (70 μg/kg) was administered to patients with an ACT above baseline and clinical signs of diffuse bleeding. Additional measurements included ACT, 2 ROTEM measurements, standard coagulation tests, coagulation factors, and an anti-Xa activity. Anti-Xa assays are the method used by laboratories to determine both heparin levels, the effects of heparin and low molecular weight heparin. In 16 patients receiving additional protamine (n = 16) doses, coagulation times significantly increased,3 but this did not occur in patients receiving a single protamine dose (n = 6). The ROTEM assay ratio correctly identified 56/58 samples as not containing circulating or uncomplexed heparin and correctly detected residual heparin in three of the only six samples showing elevated anti-Xa values after CPB. The authors suggest that ROTEM might be useful in excluding free heparin levels. One important finding from this pilot study is that, based on current dosing strategies, most patients are adequately reversed after an initial dose of protamine. In fact, most clinicians administer too much protamine as lower doses have been known for many years to be effective because heparin undergoes metabolism and plasma levels decrease as a result of time. The ROTEM assay correctly identified the presence of circulating heparin (anti-Xa = 0.17 IU/mL), while the 2 patients showing anti-Xa activity at the detection level (0.11 IU/mL and 0.13 IU/mL) and the 13 patients showing no residual heparin would not have received additional protamine. When measuring for heparin rebound after CPB, heparin levels may range from 0.1 to 0.3 IU/mL, suggesting circulating levels of heparin based on a 5 L blood volume of 500–1500 U requiring protamine doses of 5–15 mg may be effective at reversing rather than the a dose of 50 mg commonly administered. Is additional protamine administration bad? Excess protamine inhibits platelets and serine proteases involved in coagulation.4–9 However, whether protamine excess increases clinical bleeding is an important question. Despotis et al.10 reported that maintaining heparin levels during CPB and administering protamine based on the correct dose of circulating heparin reduced postoperative bleeding and the need for hemostatic factors. We reported that excess protamine prolongs the ACT and causes additional platelet dysfunction.11 Most clinicians administer excess protamine from the start based on fixed-dosing rather than actual calculated dosing based on the amount of circulating heparin. We noted protamine dosed to reverse or circulating heparin produced the lowest ACT values, similar to the study by Despotis.10 DeLaria et al.12 also reported lower protamine doses reduced bleeding and the need for allogeneic blood transfusions. However, Svenarud et al.13 reported no differences. Of interest is that heparin rebound usually occurs several hours after CPB and, as noted by the authors, a continuous postoperative protamine infusion decreases postoperative bleeding.14 From the current study, although the ROTEM assay may useful for determining the need for additional protamine administration, most patients do not need additional protamine administration immediately after their initial dose. As the authors note, they monitored the patient for only 30 min after protamine administration. Most heparin rebound is reported 2–3 h after the initial dose of protamine usually in the intensive care unit and may represent a potential cause for bleeding.15,16 This is complicated by the fact that ACT values are not a sensitive indicator of low heparin concentrations after protamine reversal, and are also influenced by platelet count and fibrinogen concentration. However, increased ACT values after protamine administration are routinely treated with additional protamine doses that may also further prolong ACT.11 Thus, avoiding excess protamine is potentially an important consideration in reducing coagulopathy after cardiac surgery. Additional important considerations for this investigation are that Anesthesia & Analgesia is receiving many submissions of in vitro hemostatic investigations that include small numbers of samples (patients) using thromboelastometry/graphy or other novel coagulation assays. It is important to note for future investigators that isolated in vitro coagulation studies using thromboelastometry/graphy need to include clinical outcomes, additional experimental assays, or other laboratory-based assays to confirm the in vitro findings. The pilot study by Mittermayr et al. is a good example of a pilot study that evaluated an important clinical concept to determine adequacy of heparin reversal compared to the standard laboratory testing. This investigation assessed the bedside ROTEM method in combination with standard laboratory tests, including coagulation factors and heparin assays, using an anti-Xa laboratory test to validate the findings, all contributing to a novel investigation of an important clinical problem. So is too much of a good thing (protamine) bad? Yes. We administer far too much protamine to treat bleeding in patients who don’t need it. What we are often treating are ACT values, not unreversed heparin. Bleeding after cardiac surgery is complex and multifactorial. Despite current evidence suggesting excess protamine contributes to bleeding, additional studies are needed to further support the growing in vitro evidence. Mittermayr et al. have demonstrated the potential of an additional bedside monitor for evaluating the need for additional protamine.
No takes yet. Share an insight, caveat, or question.
Levy et al. (2009) conducted an editorial in Coronary artery surgery with cardiopulmonary bypass (n=22). Additional protamine vs. Single protamine dose was evaluated on Coagulation times.
Synapse has enriched 10 related papers. Consider them for comparative context: